期刊
JOURNAL OF PHARMACEUTICAL SCIENCES
卷 112, 期 7, 页码 1832-1844出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.xphs.2023.04.005
关键词
Monoclonal antibody; Formulation; Oral delivery; Aggregation; Stability; Passive immunization; Secretory IgA
This study investigates the feasibility of low-cost, oral passive immunization using secretory IgA antibodies (sIgA) against enterotoxigenic Escherichia coli (ETEC). Different formulations were evaluated for stability during storage and in in vitro digestion models. The results demonstrate the potential of single-vial, liquid formulations of sIgA antibodies for passive immunization after infant feeding.
Enterotoxigenic Escherichia coli (ETEC) is a common cause for diarrheal infections in children in low-and middle-income countries (LMICs). To date, no ETEC vaccine candidates have been approved. Passive immunization with low-cost, oral formulations of secretory IgA (sIgA) against ETEC is an alternative approach to protect high-risk populations in LMICs. Using a model sIgA monoclonal antibody (anti-LT sIgA2-mAb), the stability profiles of different formulations were assessed during storage and in in vitro digestion models (mimicking in vivo oral delivery). First, by employing various physicochemical techniques and a LT-antigen binding assay, three formulations with varying acid-neutralizing capacity (ANC) were evaluated to stabilize sIgA2-mAb during stress studies (freeze-thaw, agitation, elevated temperature) and during exposure to gastric phase digestion. Next, a low-volume, in vitro intestinal digestion model was developed to screen various additives to stabilize sIgA2-mAb in the intestinal phase. Finally, combinations of high ANC buffers and decoy proteins were assessed to collectively protect sIgA2-mAb during in vitro sequential (stomach to intestine) digestion. Based on the results, we demonstrate the feasibility of low-cost, 'single-vial', liquid formulations of sIgA-mAbs delivered orally after infant feeding for passive immunization, and we suggest future work based on a combination of in vitro and in vivo stability considerations. & COPY; 2023 The Authors. Published by Elsevier Inc. on behalf of American Pharmacists Association. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据